LUNG
HealthcarePulmonx Corporation
$2.24
$-0.06 (-2.61%)
Jan 5, 2026
Price History (1Y)
Analysis
Pulmonx Corporation is a medical devices company operating within the healthcare sector. With a market capitalization of $92.39 million and annual revenue of $91.66 million, it represents a relatively small-scale player in its industry, employing 291 individuals. The company's financial health is characterized by significant losses. Net income (TTM) stands at -$56,753,000, while EBITDA amounts to -$56,060,000. The operating margin and profit margin are -66.9% and -61.9%, respectively, indicating substantial operational inefficiencies. On the other hand, the gross margin is 73.3%. In terms of returns, the Return on Equity (ROE) is -73.7%, and the Return on Assets (ROA) is -23.4%. The balance sheet shows $76.55 million in cash reserves but a significant debt burden of $56.56 million, resulting in a Debt to Equity ratio of 94.22. Pulmonx Corporation's valuation metrics are mixed. The forward P/E ratio is -1.68, and the price to sales ratio is 1.01. The company's revenue growth (YoY) stands at 5.5%, but there is no data available for Earnings Growth (YoY). Dividend information is not applicable as the dividend yield is N/A and the Payout Ratio is 0.0%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Pulmonx Corporation
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also offers LungTraX Platform, a cloud-based quantitative computed tomography analysis service that provides physicians with multiple products, such as LungTraX Connect to improve workup efficiency; LungTraX Detect to enable patient identification; and StratX Lung report that is designed for solution that includes information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
Visit website →Key Statistics
- Market Cap
- $92.39M
- P/E Ratio
- N/A
- 52-Week High
- $9.37
- 52-Week Low
- $1.31
- Avg Volume
- 2.75M
- Beta
- 0.11
Company Info
- Industry
- Medical Devices
- Exchange
- NMS
- Country
- United States
- Employees
- 291